U.S. Life Sciences Stock News

Soleno Therapeutics recently reported that its fourth-quarter 2025 results marked a shift to profitability, with net income of US$43.36 million and full-year net income of US$20.89 million, driven by the commercial launch of VYKAT XR for hyperphagia in Prader-Willi syndrome. The company also announced that long-time finance leader James Mackaness will retire and be succeeded by experienced biopharma and healthcare executive Jennifer Fulk as Chief Financial Officer, reinforcing its move from...

In February 2026, Borr Drilling reported fourth-quarter 2025 revenue of US$259.4 million and a net loss of US$1.0 million, alongside new and extended jack-up rig contracts across Mexico, Brunei, the U.S., Gabon, Congo, and offshore Germany that enhance fleet utilization and revenue visibility. An interesting angle is how this mix of lower quarterly profitability but fuller rig calendars could reshape views on Borr Drilling’s risk profile and earnings quality. Next, we’ll examine how these...

Why Black Stone Minerals Is In Focus After Its Latest Earnings Release Black Stone Minerals (BSM) is back on investors’ radar after releasing fourth quarter and full year 2025 results that highlighted higher revenue and net income, alongside fresh 2026 production guidance and detailed 2025 operating metrics. See our latest analysis for Black Stone Minerals. The earnings release and 2026 production guidance arrived after a steady run, with Black Stone Minerals’ share price showing an 11.77%...

Why the latest MRT-2359 data matters for Monte Rosa Therapeutics (GLUE) Monte Rosa Therapeutics (GLUE) is back on investors’ radar after updated clinical data for its MRT-2359 prostate cancer program, presented at the ASCO GU Symposium, supported a move into Phase 2 and potential registrational studies. See our latest analysis for Monte Rosa Therapeutics. Despite the positive MRT-2359 update and upcoming conference appearance, Monte Rosa Therapeutics’ recent momentum has cooled. The company...

TG Therapeutics recently reported fourth-quarter 2025 results showing revenue of US$192.57 million, up sharply from US$108.19 million a year earlier, while quarterly net income was essentially flat and earnings per share came in below analyst expectations. For 2025 as a whole, the company recorded US$616.29 million in revenue and a very large increase in net income to US$447.18 million, largely reflecting the growing contribution of BRIUMVI alongside raised guidance for 2026. We’ll now...

In February 2026, Ardent Health announced a partnership with hellocare.ai to roll out an enterprise AI platform for virtual nursing, telehealth, and patient safety monitoring across more than 2,000 inpatient rooms, aiming to enhance clinical capacity and standardize virtual care workflows. This move deepens Ardent’s digital transformation by combining AI-powered monitoring, purpose-built hardware, and clinical integration to create a unified, data-driven virtual care infrastructure that...

Earnings beat puts DiamondRock Hospitality (DRH) in focus Fresh off fourth quarter and full year 2025 results that topped Wall Street expectations on funds from operations, DiamondRock Hospitality (DRH) is back on investors’ radar as management outlines its next phase. See our latest analysis for DiamondRock Hospitality. At a share price of US$10.04, DiamondRock Hospitality has seen a 9.37% 1 month share price return and an 11.80% 3 month share price return, while its 1 year total shareholder...

American Healthcare REIT (AHR) has come into focus after launching and completing a sizeable at the market equity program, raising hundreds of millions of dollars alongside fresh earnings and 2026 guidance. See our latest analysis for American Healthcare REIT. The new equity program and recent capital raise come after a period of strong interest in American Healthcare REIT. The 30 day share price return is 11.36% and the year to date share price return is 10.58%, while the 1 year total...

Recent analyst upgrades on Palantir Technologies (PLTR), led by UBS and Rosenblatt, have refocused attention on the company’s role in artificial intelligence and data analytics, particularly following a sharp pullback in the share price. See our latest analysis for Palantir Technologies. Those upgrades and AI partnerships come after a sharp reset in sentiment, with a 30 day share price return of 6.41% and a 90 day share price return of 18.09% contrasted with a very large 3 year total...

Market reaction to new AI and photonics partnerships Tower Semiconductor (TSEM) has drawn fresh attention after a series of AI focused photonics partnerships, including Salience Labs, Xanadu, and Scintil Photonics, coincided with a 3.68% share price drop on 26 February. See our latest analysis for Tower Semiconductor. These AI and photonics deals come after a strong run for Tower Semiconductor, with a 90 day share price return of 11.63% and a 1 year total shareholder return of 193.81%...

In late February 2026, Ionis Pharmaceuticals reported full-year 2025 results showing revenue of US$943.71 million and a net loss of US$381.39 million, while also issuing 2026 revenue guidance of US$800 million to US$825 million. Around the same time, Ionis gained regulatory momentum with the FDA granting Priority Review to olezarsen for severe hypertriglyceridemia and new DAWNZERA Phase 3 data being highlighted at a major allergy conference, underscoring the breadth of its RNA-targeted...

If you are wondering whether Kaiser Aluminum's current share price lines up with its underlying worth, this article walks through the key signals you will want to weigh. The stock last closed at US$130.14, with returns of 0.9% over 7 days, 6.1% over 30 days, 8.2% year to date, 90.5% over 1 year, 74.0% over 3 years, and 36.6% over 5 years. This performance sets an important backdrop for any value check. Recent coverage around Kaiser Aluminum has focused on how investors view its role within...

In late February 2026, Kratos Defense & Security Solutions completed a large follow-on equity offering of 14,285,714 common shares at US$84.00 each, raising about US$1.17 billion to fund capital investment, product development, acquisitions and general corporate purposes under a newly filed universal shelf. Alongside this capital raise, Kratos advanced several defense programs, including a zero-lien Critical Design Review for the Space Development Agency’s Advanced Fire Control Ground...

Broadstone Net Lease, Inc. recently reported fourth-quarter and full-year 2025 results alongside a board-approved quarterly dividend of US$0.2925 per share, while also adding two new build-to-suit development projects in Florida and Texas with an estimated total investment of about US$62.1 million. The combination of fresh industrial and retail development commitments and a higher dividend highlights management’s confidence in its growth pipeline and tenant relationships. Next, we’ll explore...

If you are wondering whether Navigator Holdings is still reasonably priced after its recent run, you are not alone. This article will focus on what the current share price might be telling you about its underlying value. The stock last closed at US$21.02, with returns of 4.1% over 7 days, 13.4% over 30 days, 21.2% year to date, 40.4% over 1 year, 54.8% over 3 years and 115.2% over 5 years. This naturally raises questions about how much optimism is already built into the price. Recent...

Public Storage (NYSE:PSA) is relocating its corporate headquarters from California to North Texas, alongside a leadership transition. The company has also entered a data science partnership with Welltower to support capital allocation and operational analytics. Both moves mark a shift in how Public Storage organizes its operations and uses data to run its self storage platform. For investors watching NYSE:PSA, these corporate decisions sit alongside a share price of $307.06 and a value...

If you are looking at Acadia Realty Trust and wondering whether the current share price gives you good value, this article will walk through what the numbers are actually saying. The stock last closed at US$20.92, with returns of 3.2% over 7 days, 4.5% over 30 days, 1.4% year to date, a 5.6% decline over 1 year, 62.7% over 3 years and 30.0% over 5 years. Together, these figures provide a wide mix of recent and longer term outcomes to think about. Recent moves in Acadia Realty Trust's share...

Perimeter Solutions (NYSE:PRM) is dealing with operational and safety issues at its Sauget P2S5 facility that have led to reduced production and ongoing litigation as it seeks to take control of the site. The company has recently closed a sizeable acquisition while shifting more of its portfolio toward fixed and recurring contracts to support more consistent earnings. These developments affect a key production asset and the structure of Perimeter Solutions' revenue, with potential...

In recent weeks, UGI Utilities has begun additional natural gas system upgrades in Lancaster and implemented higher purchased gas cost rates, while its proposal for a US$99.40 million annual distribution rate increase has been temporarily suspended by the Pennsylvania Public Utility Commission for further review. Together, these infrastructure investments, customer bill impacts, and regulatory oversight highlight how UGI’s earnings profile is closely tied to state-level rate decisions and...

IDACORP, Inc. recently reported its full-year 2025 results, with sales of US$1.81 billion, revenue of US$1.81 billion, and net income rising to US$323.47 million, alongside higher basic and diluted earnings per share from continuing operations compared with 2024. At the same time, the company issued 2026 earnings guidance of US$6.25 to US$6.45 per diluted share, highlighting management’s expectations while signaling limited use of additional tax credits under Idaho’s regulatory...

Regeneron Pharmaceuticals (NasdaqGS:REGN) received FDA approval for Dupixent as the first treatment for allergic fungal rhinosinusitis, a chronic nasal disease. The FDA also accepted garetosmab for Priority Review for treating fibrodysplasia ossificans progressiva, a rare and serious genetic disorder. For you as an investor, these decisions highlight where Regeneron focuses its efforts: targeted biologic therapies in areas with limited existing options. Dupixent already sits at the center...

If you are wondering whether Sirius XM Holdings is still priced fairly after everything that has happened to the stock, this article walks through what the current share price could mean for long term investors. The stock recently closed at US$21.96, with returns of 4.3% over 7 days and 7.9% over 30 days, while the 1 year return sits at a 4.5% decline and the 3 and 5 year returns are 42.3% and 55.6% declines. Those mixed returns have arrived against a backdrop of ongoing product, content and...

Sonos (SONO) has become a talking point after EXL announced a transformation initiative with Sonos and Amazon Web Services to deploy agentic AI within Sonos IT service management workflows, targeting efficiency, operational intelligence, and risk mitigation. See our latest analysis for Sonos. The latest AI initiative sits against a mixed share price backdrop, with Sonos trading at US$15.40 and showing a 7.3% 1 month share price return but a 17% 3 month share price decline. The 1 year total...

Sotera Health (SHC) shares were in focus after the company reported stronger fourth quarter and full year 2025 earnings and provided new 2026 revenue guidance, outlining expected net revenues of US$1.233b to US$1.251b. See our latest analysis for Sotera Health. The recent earnings beat, new 2026 revenue guidance and upcoming leadership change around the General Counsel role arrive after a softer patch for the stock, with a 30 day share price return of 10.32% decline and a 1 year total...